
BTHE
Healthcare · Biotechnology · $9.2M market cap
Latest report
Time not confirmed
The next earnings date isn’t on the calendar yet.
Analyst consensus
Analyst estimates aren’t available for this symbol.
Beat estimates in 0 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Aug 12, 2021 | Time not confirmed | — | -0.00 | — |
| May 18, 2021 | Time not confirmed | — | -0.02 | — |
| Mar 31, 2021 | Time not confirmed | — | -0.02 | — |
| Dec 31, 2020 | Time not confirmed | — | -0.00 | — |
| Sep 30, 2020 | Time not confirmed | — | -0.00 | — |
| Jun 30, 2020 | Time not confirmed | — | -0.00 | — |
| Mar 31, 2020 | Time not confirmed | — | -0.00 | — |
| Dec 31, 2019 | Time not confirmed | — | -0.02 | — |
| Sep 30, 2019 | Time not confirmed | — | -0.00 | — |
| Jun 30, 2019 | Time not confirmed | — | -0.00 | — |
| Mar 31, 2019 | Time not confirmed | — | -0.01 | — |
| Dec 31, 2018 | Time not confirmed | — | -0.01 | — |
| Sep 30, 2018 | Time not confirmed | — | 0.01 | — |
| Jun 30, 2018 |
Boston Therapeutics, Inc. develops, manufactures, and commercializes therapeutic drugs to address unmet medical needs in diabetes and inflammatory diseases. The company develops BTI-320, a non-systemic carbohydrate-based compound tablet that is in Phase II clinical trial for reduction of post-meal blood glucose levels in pre-diabetes patients and type 2 diabetes patients; and IPOXYN, an injectable drug to prevent…
| Time not confirmed |
| — |
| -0.00 |
| — |
| Mar 31, 2018 | Time not confirmed | — | -0.03 | — |